BioNTech is a German biotechnology company that specializes in the development of innovative therapies and vaccines, particularly focusing on messenger RNA (mRNA) technology. Founded in 2008, the company gained significant recognition for its role in developing one of the first effective COVID-19 vaccines in collaboration with Pfizer. BioNTech aims to create personalized immunotherapies for cancer treatment, as well as vaccines for infectious diseases, leveraging its proprietary mRNA platform to target various medical conditions more effectively. The company’s mission integrates cutting-edge research with a commitment to improving patient outcomes through advanced biopharmaceutical solutions.
BioNTech is shifting its focus from COVID-19 vaccines to pioneering mRNA-based cancer therapies, with goals for market approval by 2026. In 2023, profits declined significantly, with revenue projections for 2024…